SEC Form 4 · accession 0001209191-15-022576
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent P Ippolito
Officer — EVP & Chief Commercial Officer
Period of report
Mar 3, 2015
Accepted (ET)
Mar 4, 2015 · 7:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 3, 2015 | S | 7,846 | $43.8138 | D | 71,757 | D | |
| Common StockF3 | Mar 3, 2015 | S | 1,154 | $44.3445 | D | 70,603 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person to cover taxes associated with the vesting of restricted stock units.
- F2The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.24 to $44.16, inclusive.
- F3The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.30 to $44.42, inclusive.